Get the Stockscreener App
24.30
1.46%
-0.36
After Hours:
24.34
0.04
+0.16%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $24.30, with a volume of 165.67M.
It is down -1.46% in the last 24 hours and down -11.22% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$24.66
Open:
$24.39
24h Volume:
165.67M
Relative Volume:
2.99
Market Cap:
$138.16B
Revenue:
$63.83B
Net Income/Loss:
$10.77B
P/E Ratio:
12.93
EPS:
1.8799
Net Cash Flow:
$12.44B
1W Performance:
-0.82%
1M Performance:
-11.22%
6M Performance:
+0.41%
1Y Performance:
-12.46%
1-Day Range:
$24.20
$25.20
1-Week Range:
$24.15
$25.20
52-Week Range:
$20.91
$28.00
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.30 | 140.21B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
906.86 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.86 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
215.89 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
125.01 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.86 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer Receives Early Termination of FTC Review for Metsera Acquisition - geneonline.com
Pfizer Q3 Revenue Falls 7% To US$16.7 Billion - BusinessToday Malaysia
Defining The 'Superior' Bid In Pfizer-Novo Legal Battle - Law360
Pfizer, Novo Nordisk escalate bidding war for obesity drug developer Metsera - Denver Gazette
Pfizer’s Earnings Call: Strategic Gains Amid Challenges - TipRanks
Pfizer (NYSE:PFE) Trading Down 1.4%Time to Sell? - MarketBeat
PFIZER INC : JP Morgan is Neutral - MarketScreener
Metsera in the middle of Novo, Pfizer bidding war - BioWorld MedTech
Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup MetseraWSJ - The Wall Street Journal
Pfizer and Novo fatten their bids for weight-loss drugmaker Metsera - Axios
Pfizer Weight-Loss $9B Suit: Delaware Court Holds Off Amid High-Stakes Fight Over Metsera - USA Herald
Pfizer ‘Unwavering’ In Pursuit Of Metsera - Citeline News & Insights
Pfizer Earnings: In-Line Quarter Despite Covid Product Weakness as Metsera Drama Intensifies - Morningstar
Pfizer Inc (PFE) Q3 2025 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... By GuruFocus - Investing.com Canada
Pfizer Inc (PFE) Q3 2025 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... - Yahoo Finance
Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk - Financial Times
Novo Nordisk Boosts Metsera Bid To $10B After Pfizer Suit - Law360
Pfizer Can't Freeze $9B Weight-Loss Drug Fight For Now - Law360
How Pfizer's (PFE) Metsera Legal Fight and Q3 Dip Could Reshape Its Innovation Strategy - Yahoo Finance
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It - Benzinga
Traders Purchase Large Volume of Pfizer Call Options (NYSE:PFE) - MarketBeat
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb - Benzinga
Novo Nordisk ups Metsera offer to $10B, outbidding Pfizer - The Business Journals
Pfizer Is Losing Its Fight With Novo Nordisk to Get Back in the Obesity-drug Game - 富途牛牛
Pfizer Narrows Its Outlook And Keeps The Optimism Flowing - Finimize
Novo Nordisk Outbids Pfizer In $10 Billion Metsera Takeover Battle - Finimize
Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera - Barron's
Novo, Pfizer Boost Metsera Bids in Obesity Startup Battle - MarketScreener
Pfizer Q3 Revenue Trends Are Uneven, Cost Cuts Drive EarningsPfizer (NYSE:PFE) - Benzinga
Pfizer Profit Falls Amid Lower Covid-19 Drug Demand - The Wall Street Journal
Pfizer Stock Falls on Third-Quarter Earnings. What Covid-19 Has to Do With It. - Barron's
Pfizer, Novo Boost Bids for Obesity Drugmaker Metsera in Takeover Saga - Bloomberg
Pfizer Q3 2025 slides: EPS beats expectations as company raises guidance - Investing.com
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera - Proactive financial news
Metsera’s Shares Spike Amid Acquisition Proposals from Novo Nordisk and Pfizer - StocksToTrade
Pfizer (PFE) Q3 2025 Earnings Call Transcript - The Globe and Mail
Transcript : Pfizer Inc., Q3 2025 Earnings Call, Nov 04, 2025 - MarketScreener
Delaware court won't rule on Pfizer/Novo battle for Metsera today - Seeking Alpha
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo - Reuters
Metsera again chooses Novo as bidding war with Pfizer intensifies - BioPharma Dive
Pfizer : Quarterly Corporate PerformanceThird Quarter 2025 Prepared Remarks - MarketScreener
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up - Yahoo Finance
Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer - Houston Chronicle
Pfizer reports strong Q3 earnings, raises full-year profit guidance - Proactive financial news
Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools - TradingView
Pfizer’s Q3 Earnings Beat on Top and Bottom Lines - AOL.com
Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025 - MarketScreener
Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup - The Wall Street Journal
Pfizer & Novo boost Metsera bids, Hertz stock skyrockets - Yahoo Finance
Novo Nordisk Hikes Metsera Bid to up to $10B in Competition With Rival Pfizer - U.S. News & World Report
Global markets live: Tesla, Amazon, Palantir, Pfizer, Merck… - MarketScreener
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):